What evidence supports the use of sodium bicarbonate in sepsis, and what are the appropriate indications, dosing, and monitoring?

Sodium Bicarbonate in Sepsis: Evidence-Based Recommendation

Do not use sodium bicarbonate therapy to improve hemodynamics or reduce vasopressor requirements in septic patients with hypoperfusion-induced lactic acidemia when pH ≥ 7.15. 1

Guideline-Based Approach

The Surviving Sepsis Campaign 2016 guidelines provide clear direction: sodium bicarbonate should not be administered for the purpose of improving hemodynamics or reducing vasopressor requirements when pH is 7.15 or higher (weak recommendation, moderate quality evidence). This represents the current standard of care and should guide clinical decision-making in the vast majority of septic patients with metabolic acidosis.

The pH 7.15 Threshold

The critical decision point is pH 7.15:

• pH ≥ 7.15: Avoid bicarbonate for hemodynamic indications
• pH < 7.15: Bicarbonate may be considered, though guidelines do not make explicit recommendations below this threshold

This threshold exists because the evidence does not support hemodynamic benefit above pH 7.15, and the risks of bicarbonate therapy (hypernatremia, metabolic alkalosis, hypocalcemia, volume overload) outweigh uncertain benefits.

Recent High-Quality Evidence

The SODa-BIC Trial (2026)

The most recent and highest-quality evidence comes from the SODa-BIC trial 2, which enrolled 500 critically ill adults with metabolic acidosis (pH < 7.30) receiving vasopressors. This trial found no benefit of sodium bicarbonate versus placebo for the primary outcome of major adverse kidney events (40.2% vs 39.4%, p=0.78), renal replacement therapy use (16.8% vs 20.9%), or 30-day mortality (25.4% vs 24.0%).

This 2026 trial directly contradicts the theoretical rationale for bicarbonate use and reinforces the guideline recommendation against routine use.

The BICAR-ICU Trial (2018)

The BICAR-ICU trial 3 enrolled 389 patients with severe acidemia (pH ≤ 7.20) and found no benefit for the primary composite outcome. However, in the prespecified subgroup with acute kidney injury (AKIN score 2-3), bicarbonate significantly improved 28-day survival (54% vs 37%, p=0.0283).

This suggests a potential exception: patients with severe acidemia (pH ≤ 7.20) AND established acute kidney injury may benefit from bicarbonate therapy, though this requires confirmation in dedicated trials.

When Bicarbonate May Be Considered

Based on FDA labeling 4 and available evidence, sodium bicarbonate has established indications in:

1. Severe metabolic acidosis with pH < 7.15 in the context of:

   • Cardiac arrest (rapid IV: 44.6-100 mEq initially, then 44.6-50 mEq every 5-10 minutes as needed)
   • Severe acute kidney injury with pH ≤ 7.20 (based on BICAR-ICU subgroup)
   • Drug intoxications (barbiturates, salicylates, methanol)
   • Hemolytic reactions requiring urine alkalinization

2. Dosing for metabolic acidosis (when indicated):

   • Adults: 2-5 mEq/kg over 4-8 hours
   • Target: Gradual correction to pH ~7.30 (not full normalization in first 24 hours)
   • Monitor: Arterial blood gases, serum electrolytes (sodium, calcium), plasma osmolarity

Critical Monitoring Parameters

When bicarbonate is administered:

• Arterial pH and blood gases every 1-2 hours initially
• Serum sodium: Risk of hypernatremia (bicarbonate solutions are hypertonic)
• Serum calcium: Risk of hypocalcemia
• Plasma osmolarity: Risk of hyperosmolarity
• Clinical response: Hemodynamics, lactate clearance, organ function

Common Pitfalls to Avoid

1. Overcorrection: Attempting to normalize pH to >7.40 in the first 24 hours leads to metabolic alkalosis due to delayed ventilatory adjustment
2. Ignoring the pH threshold: Using bicarbonate at pH ≥ 7.15 for hemodynamic support lacks evidence and exposes patients to harm
3. Rapid bolus administration: Except in cardiac arrest, bicarbonate should be infused over 4-8 hours to avoid acute electrolyte shifts
4. Neglecting underlying cause: Bicarbonate is adjunctive; source control, antibiotics, and fluid resuscitation remain primary interventions

Emerging Evidence Considerations

A 2026 meta-analysis 5 of 1,111 patients showed bicarbonate significantly reduced RRT requirement (RR 0.69,95% CI 0.61-0.78) with a nonsignificant trend toward lower mortality (RR 0.84,95% CI 0.55-1.30). However, the mortality evidence remains inconclusive with insufficient sample size, and the RRT benefit may reflect the BICAR-ICU AKI subgroup effect rather than a generalizable benefit.

Recent observational data 6 identified a J-shaped relationship between serum bicarbonate and mortality, with optimal levels between 24.0-26.4 mmol/L. This suggests maintaining bicarbonate in the normal-to-slightly-low range may be preferable to aggressive correction.

Bottom Line Algorithm

For septic patients with lactic acidosis:

1. Check arterial pH

   • pH ≥ 7.15: Do not give bicarbonate for hemodynamic indications
   • pH < 7.15 without AKI: Consider bicarbonate cautiously; evidence is limited
   • pH ≤ 7.20 with AKIN 2-3 AKI: Consider bicarbonate (2-5 mEq/kg over 4-8 hours, target pH 7.30)

2. Focus on primary interventions: Source control, antibiotics, fluid resuscitation, vasopressors

3. If bicarbonate is given: Monitor pH, electrolytes, and osmolarity closely; avoid overcorrection

The weight of guideline evidence 1 and the most recent high-quality trial 2 support withholding bicarbonate in most septic patients, with possible exception for severe acidemia with established AKI based on BICAR-ICU subgroup analysis 3.